Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Treatment of severe hypoglycemia outside of the hospital setting is limited to glucagon formulations requiring reconstitution before use, which may lead to erroneous or delayed glucagon administration. We compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety and tolerability of different doses of dasiglucagon, a novel soluble glucagon analog, with approved pediatric and full doses of GlucaGen in insulin-induced hypoglycemia in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion. RESULTS: Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h. Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9–14 min) to PG ≥70 mg/dL (within 6–10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG. All patients on both treatments reached these end points within 30 min (predefined success criteria). Both treatments were well tolerated. Nausea was the most frequent adverse event, occurring at a similar rate (44–56%). CONCLUSIONS: Dasiglucagon was well tolerated and showed an early PD response similar to that of GlucaGen at corresponding doses, suggesting comparable clinical effects of the two glucagon formulations. Dasiglucagon has the potential to become an effective and reliable rescue treatment for severe hypoglycemia in a ready-to-use pen.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These new FDAeapproved formulations have demonstrated glycemic responses similar to standard glucagon formulations for the treatment of hypoglycemia but without the need of reconstitution.1230”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1230]
Citations
Cites
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 254
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233 · cited 1×
“As advantageous as this design was for creating similar baseline conditions, this setup is different from the usual clinical causes of severe hypoglycemia, whichmost often comprise of insulin dosing errors, exercise, and alcohol consumption (30).”
BackgroundHaidar, A., Legault, L., Messier, V., Mitre, T. M., Leroux, C., & Rabasa-Lhoret, R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70226-8 · Cited by 214 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundTreatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Kedia (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s20633 · Cited by 150
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1498 · Cited by 137
Haidar, A., Legault, L., Matteau‐Pelletier, L., Messier, V., Dallaire, M., Ladouceur, M., & RABASA-LHORET, R. P. R. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00141-2 · Cited by 129 · cited 1×
“tems have been demonstrated in adults, adolescents, and children (20,21).”
BackgroundLecavalier, L., Bolli, G. B., Cryer, P., & Gerich, J. E. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.256.6.e844 · Cited by 125
Mini-Dose Glucagon Rescue for Hypoglycemia in Children With Type 1 Diabetes
Haymond, M. W., & Schreiner, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.643 · Cited by 112 · cited 2×
“cemia rescue therapy, glucagondoses in the artificial pancreas setting are much smaller and have been reported to be effective in themanagement of mild or expected forthcoming hypoglycemia in a range of 20–150 mg in children and adolescents with type 1 diabetes (22,23).”
BackgroundTaborsky, G. J. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400607 · Cited by 96
Jacobs, P. G., Youssef, J. E., Castle, J. R., Bakhtiani, P. A., Branigan, D. L., Breen, M. E., Bauer, D., Preiser, N., Leonard, G., Stonex, T. M., et al. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2323248 · Cited by 90
The Nature of Amyloid-like Glucagon Fibrils
Pedersen, J. S. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400609 · Cited by 81
Glucagon administration – underevaluated and undertaught
Harrism, G., Diment, A., Sulway, M. J., & Wilkinson, M. (2001) · Practical Diabetes · doi:10.1002/pdi.138 · Cited by 71 · cited 2×
“Despite training, the reconstitution process could still lead to erroneous or delayed administration of glucagon, at least when used by medical nonprofessionals in stressful emergency situations (1,2).”
BackgroundOptimization of the Native Glucagon Sequence for Medicinal Purposes
Chabenne, J. R., DiMarchi, M. A., Gelfanov, V. M., & DiMarchi, R. D. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400605 · Cited by 65 · cited 1×
“One of the first developments reported by Chabenne and colleagues uses a pH adjustment and backbone stabilization to achieve aqueous solubility and stability (12,13).”
BackgroundA glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia
Chabenne, J. R., Chabenne, M. D., Zhao, Y., Levy, J. J., Smiley, D., Gelfanov, V. M., & DiMarchi, R. D. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.006 · Cited by 64 · cited 1×
“One of the first developments reported by Chabenne and colleagues uses a pH adjustment and backbone stabilization to achieve aqueous solubility and stability (12,13).”
BackgroundDiabetes Research in Children Network (DirecNet) Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2298 · Cited by 61
El Youssef, J., Castle, J. R., Bakhtiani, P. A., Haidar, A., Branigan, D. L., Breen, M., & Ward, W. K. (2014) · Diabetes Care · doi:10.2337/dc14-0803 · Cited by 52 · cited 1×
“This is in particular important for prevailing insulin levels, as high insulin concentrations have been shown to partially prevent glucagon from increasing endogenous glucose production and thereby affecting glucagon efficacy (29).”
BackgroundNewswanger, B., Ammons, S., Phadnis, N. V., Ward, W. K., Castle, J. R., Campbell, R. W., & Prestrelski, S. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814565131 · Cited by 51
Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels
Blauw, H., Wendl, I., DeVries, J. H., Heise, T., & Jax, T. W. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12571 · Cited by 47 · cited 1×
“00 mg administered in euglycemic or hypoglycemic baseline conditions (25).”
BackgroundSelf-citationStabilized Glucagon Formulation for Bihormonal Pump Use
Steiner, S. S., Li, M., Hauser, R. G., & Pohl, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400606 · Cited by 40
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39 · cited 1×
“Likewise, low-dose glucagon boluses of 100–300mg were demonstrated to effectively increase PG levels of 54mg/dL after insulin overdosing in pump users (24).”
BackgroundHartley, M., Thomsett, M. J., & Cotterill, A. M. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00807.x · Cited by 36 · cited 1×
“cemia rescue therapy, glucagon doses in the artificial pancreas setting are much smaller and have been reported to be effective in the management of mild or expected forthcoming hypoglycemia in a range of 20–150 mg in children and adolescents with type 1 diabetes (22,23).”
BackgroundDevelopment of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas
Pohl, R., Li, M., Krasner, A., & De Souza, E. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814555541 · Cited by 29
Rickels, M. R., Ruedy, K. J., Foster, N. C., Piché, C. A., Dulude, H., Sherr, J. L., Tamborlane, W. V., Bethin, K. E., DiMeglio, L. A., Wadwa, R. P., et al. (2016) · Diabetes Care · doi:10.2337/dci16-0025 · Cited by 13
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 244
“Unfortunately, however, these preventative strategies are difficult to implement, especially if heathier habits are not pursued by the extended household or family.”
BackgroundStructural insights into differences in G protein activation by family A and family B GPCRs
Hilger, D., Kumar, K. K., Hu, H., Pedersen, M. F., O’Brien, E. S., Giehm, L., Jennings, C., Eskici, G., Inoue, A., Lerch, M. T., et al. (2020) · Science · doi:10.1126/science.aba3373 · Cited by 158
“Ligands and their sources were as follows: (-)-isoproterenol hydrochloride (Sigma-Aldrich) for b2AR; serotonin (5-hydroxytryptamine hydrochloride; FUJIFILMWakoPureChemical) for 5-HT4; prostaglandin D2 (Cayman Chemical) for DP; histamine dihydrochloride (FUJIFILM Wako Pure Chemical) for H2R; arginine vasopressin (Pepti…”
MethodInfluentialCastle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
“A stable glucagon formulation to enable longer-term use is not yet commerciallyavailable,althoughmultiple formulations are in development (33,34).”
Background
Metadata
- Authors
- Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T.
- Affiliations
- Profil Institute for Metabolic Research (DE)
- Zealand Pharma (Denmark) (DK)
- Corresponding author
- Hövelmann, Ulrike
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-22
- Volume
- 41
- Issue
- 3
- Pages
- 531-537
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2781395153
- Cited by
- 115
- References
- 26
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 17 · 2022: 18 · 2021: 26 · 2020: 7 · 2019: 15 · 2018: 6
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- dasiglucagon, glucagon analog, severe hypoglycemia, type 1 diabetes, insulin-induced hypoglycemia, pharmacokinetics, pharmacodynamics, subcutaneous injection, salvage therapy, glycemic response, nausea, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon, Half-Life, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.